CG Oncology director sells 5,000 shares

CG Oncology director Leonard E. Post reported an option exercise and share sale.

Rhea-AI Filing Summary

CG Oncology director Leonard E. Post reported an option exercise and share sale. On June 22, 2026, he exercised options to acquire 5,000 shares of common stock at $0.60 per share and sold 5,000 shares at $65.00 in an open-market transaction. The sale was executed under a Rule 10b5-1 trading plan adopted on March 5, 2026. Following these transactions, he reported no directly held common shares but retained 111,077 director stock options with a $0.60 exercise price expiring on July 8, 2028.

Insider Trade Summary 10b5-1

Exercise and Sale: 5,000 shares ($322K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider POST LEONARD E

Role Director

Sold 5,000 shs ($325K)

Approx. gross sale proceeds $325K

Approx. exercise cost $3K

Approx. pre-tax spread $322K

Type	Security	Shares	Price	Value
Exercise	Director Stock Option (right to buy)	5,000	$0.00	$0.00
Exercise	Common Stock	5,000	$0.60	$3K
Sale	Common Stock	5,000	$65.00	$325K

Holdings After Transaction: Director Stock Option (right to buy) — 111,077 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (2)

1. F1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.
2. F2. Fully vested

Key Figures

Shares sold: 5,000 shares Sale price: $65.00 per share Option exercise price: $0.60 per share +4 more

7 metrics

Shares sold 5,000 shares Common stock sold in open-market transaction on June 22, 2026

Sale price $65.00 per share Price for 5,000 common shares sold

Option exercise price $0.60 per share Exercise price for director stock options

Options exercised 5,000 options Director stock options exercised into common stock

Options remaining 111,077 options Director stock options held after transactions

10b5-1 plan adoption date March 5, 2026 Date trading plan for sales was adopted

Option expiration July 8, 2028 Expiration date for remaining director stock options

Key Terms

Rule 10b5-1 trading plan, open-market sale, Director Stock Option (right to buy), derivative security

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Director Stock Option (right to buy) financial

"security_title: Director Stock Option (right to buy)"

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CG Oncology (CGON) director Leonard E. Post report?

Leonard E. Post reported exercising options for 5,000 CG Oncology shares at $0.60 and selling 5,000 common shares at $65.00. The filing shows this was an open-market sale combined with an option exercise on June 22, 2026.

At what prices did Leonard E. Post exercise and sell CG Oncology (CGON) shares?

He exercised director stock options at an exercise price of $0.60 per share and sold 5,000 common shares at $65.00 per share. These prices come directly from the reported Form 4 transaction details for June 22, 2026.

Was the CG Oncology (CGON) director’s share sale made under a Rule 10b5-1 plan?

Yes. The footnotes state the sales were effected under a Rule 10b5-1 trading plan adopted on March 5, 2026. Such plans prearrange trades, indicating the timing of this transaction was scheduled in advance rather than decided spontaneously.

How many CG Oncology (CGON) shares did Leonard E. Post hold after the reported sale?

After selling 5,000 common shares, the filing shows he held zero shares of common stock directly. However, he continued to hold director stock options, so his overall economic exposure remains through these derivative securities rather than direct share ownership.

What director stock options in CG Oncology (CGON) does Leonard E. Post retain?

He retains 111,077 director stock options with an exercise price of $0.60 per share, expiring on July 8, 2028. These options give him the right to buy CG Oncology common stock at that fixed price before the expiration date.

How large was Leonard E. Post’s CG Oncology (CGON) sale compared with his options position?

He sold 5,000 common shares while retaining 111,077 director stock options. This means the reported sale represents only a small portion of the shares he could acquire through his remaining options, based on the figures in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

POST LEONARD E

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

3000 PEGASUS PARK DRIVE, SUITE 1640

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/22/2026		M		5,000	A	$0.6	5,000	D
Common Stock	06/22/2026		S(1)		5,000	D	$65	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$0.6	06/22/2026		M			5,000	(2)	07/08/2028	Common Stock	5,000	$0	111,077	D

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.

2. Fully vested

	/s/ Joshua F. Patterson, Attorney-in-Fact for Leonard Post	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)